INSMED Inc — Director's Dealing 2020

Aug 13, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: INSMED Inc (INSM)
CIK: 0001104506
Period of Report: 2020-05-15

Reporting Person: Schaeffer Orlov S Nicole (Chief People Strategy Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-15	Common Stock	F	1126	$25.46	Disposed	35227	Direct
2020-08-11	Common Stock	M	3761	$6.96	Acquired	38988	Direct
2020-08-11	Common Stock	S	3761	$30.07	Disposed	35227	Direct
2020-08-12	Common Stock	M	465	$6.96	Acquired	35692	Direct
2020-08-12	Common Stock	S	465	$28.77	Disposed	35227	Direct
2020-08-12	Common Stock	M	4000	$12.44	Acquired	39227	Direct
2020-08-12	Common Stock	S	4000	$28.80	Disposed	35227	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-08-11	Stock Option (right to buy)	$6.96	M	3761	Disposed	2023-01-02	Common Stock (3761)	Direct
2020-08-12	Stock Option (right to buy)	$6.96	M	465	Disposed	2023-01-02	Common Stock (465)	Direct
2020-08-12	Stock Option (right to buy)	$12.44	M	4000	Disposed	2023-05-23	Common Stock (4000)	Direct

Footnotes

F1: Represents the withholding of shares of common stock to satisfy tax withholding obligations in connection with the vesting of restricted stock units. This transaction was not reported previously due to a clerical error.

F2: This is the weighted average sales price representing 3,761 shares sold at prices ranging from $30.00 to $30.45 per share. The number sold at each price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

F3: This is the weighted average sales price representing 465 shares sold at prices ranging from $28.75 to $28.79 per share. The number sold at each price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

F4: This is the weighted average sales price representing 4,000 shares sold at prices ranging from $28.71 to $28.95 per share. The number sold at each price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.

F5: The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

F6: On May 23, 2013, the reporting person was granted an option to purchase 25,000 shares of common stock. The option vests in two installments based upon the Issuer's satisfaction of two separate performance metrics. The first installment vested on February 26, 2015. The performance metric applicable to the second installment, the first written approval of a New Drug Application or Marketing Authorization Application from the Food and Drug Administration of European Medicines Agency, respectively, was met on September 28, 2018, resulting in the vesting of the second installment.